Abciximab 10mg/5ml solution for injection vials
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Abciximab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Abciximab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
25 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · Randomised trials: 17 · 1996–2022
Showing the 50 most relevant studies, sorted by most relevant.
G. De Luca, H. Suryapranata, G. Stone, et al.
JAMA, 2005
- Abciximab
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
G. Montalescot, D. Antoniucci, A. Kastrati, et al.
European heart journal, 2007
- Stents
- Abciximab
- Antibodies, Monoclonal
CAPTURE, STGRP, non vooting member Tijssen, J.
The Lancet, 1997
- Angioplasty, Balloon, Coronary
- Abciximab
- Angina, Unstable
A. Kastrati, J. Mehilli, F. Neumann, et al.
JAMA, 2006
- Clopidogrel
- Abciximab
- Angina Pectoris
The Lancet, 2001
- Abciximab
- Tenecteplase
- Antibodies, Monoclonal
M. L. Simoons
The Lancet, 2001
- Abciximab
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
Carlo di Mario, D. Dudek, F. Piscione, et al.
Lancet, 2008
M. Valgimigli, G. Percoco, P. Malagutti, et al.
JAMA, 2005
- Stents
- Abciximab
- Tirofiban
Julinda Mehilli, Adnan Kastrati, Helmut Schühlen, et al.
Circulation, 2004
- Clopidogrel
- Abciximab
- Antibodies, Monoclonal
M. Valgimigli, G. Campo, G. Percoco, et al.
JAMA, 2008
- Abciximab
- Tirofiban
- Antibodies, Monoclonal
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
153 found
Half-life
10 minutes
Mechanism
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of…
Food interactions
1 warning
Human targets
5 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
10 minutes
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 985 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain (By similarity). Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen .
PMID:9111081
This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).
ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling .
PMID:23125415 PMID:24789099
ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling .
PMID:20682778
ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling .
PMID:18441324
ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling .
PMID:28302677
ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling .
PMID:19578119
ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling .
PMID:28873464
ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling .
PMID:29030430
ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 .
PMID:18635536 PMID:25398877
ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 .
PMID:12807887
In brain, plays a role in synaptic transmission and plasticity. Involved in the regulation of the serotonin neurotransmission, is required to localize to specific compartments within the synapse the serotonin receptor SLC6A4 and for an appropriate reuptake of serotonin. Controls excitatory synaptic strength by regulating GRIA2-containing AMPAR endocytosis, which affects AMPAR abundance and composition (By similarity).
ITGAV:ITGB3 act as a receptor for CD40LG .
PMID:31331973
ITGAV:ITGB3 acts as a receptor for IBSP and promotes cell adhesion and migration to IBSP PMID:10640428
Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen .
PMID:9111081
This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface (By similarity)
Promotes phagocytosis of opsonized antigens
Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis
Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway
ATC B01AC13
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Abciximab
Additional database identifiers
Drugs Product Database (DPD)
61
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6156
GenAtlas
ITGB3
GeneCards
ITGB3
GenBank Gene Database
J02703
GenBank Protein Database
306786
Guide to Pharmacology
2457
UniProt Accession
ITB3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6138
GenAtlas
ITGA2B
GeneCards
ITGA2B
GenBank Gene Database
J02764
GenBank Protein Database
190068
Guide to Pharmacology
2441
UniProt Accession
ITA2B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3616
GenAtlas
FCGR2A
GeneCards
FCGR2A
GenBank Gene Database
M31932
GenBank Protein Database
182474
UniProt Accession
FCG2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3618
GenAtlas
FCGR2B
GeneCards
FCGR2B
GenBank Gene Database
U87560
GenBank Protein Database
4099445
UniProt Accession
FCG2B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12724
GenAtlas
VTN
GeneCards
VTN
GenBank Gene Database
X03168
GenBank Protein Database
36575
UniProt Accession
VTNC_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Wikipedia article
glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures
Read on WikipediaATC classifications (Wikidata)
Linked open data from Wikidata (Q307088), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.